Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001581280-26-000040
| (In thousands, except per share data) | Three months ended March 31, 2026 | Three months ended March 31, 2025 | Six months ended March 31, 2026 | Six months ended March 31, 2025 |
|---|---|---|---|---|
| Revenues[1] | $110,715 | $92,793 | $214,413 | $181,506 |
| Costs and expenses: | ||||
| Cost of revenues | $53,593 | $46,765 | $103,319 | $92,638 |
| Research and development expenses | 19,695 | 23,917 | 36,825 | 45,224 |
| Selling, general and administrative expenses[1] | 76,085 | 63,671 | 145,827 | 119,849 |
| Litigation settlement costs, net of recoveries | 7,205 | — | 7,205 | — |
| Total costs and expenses | $156,578 | $134,353 | $293,176 | $257,711 |
| Loss from operations | $(45,863) | $(41,560) | $(78,763) | $(76,205) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Twist Bioscience Corporation's R&D?
- Twist Bioscience Corporation (TWST) reported R&D of $19.7M in Q1 2026.
- How has Twist Bioscience Corporation's R&D changed year-over-year?
- Twist Bioscience Corporation's R&D decreased by 17.7% year-over-year, from $23.92M to $19.7M.
- What is the long-term trend for Twist Bioscience Corporation's R&D?
- Over 4 years (2021 to 2025), Twist Bioscience Corporation's R&D has grown at a 3.8% compound annual growth rate (CAGR), from $69.07M to $80.29M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Twist Bioscience Corporation's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude